Mechanistic insights into the synergistic interactions between macrolides and beta-lactams in bacterial infections
7 affiliations
- 1Department of Pediatrics, Affiliated Jinhua Hospital, Zhejiang University School of Medicine , ,
- 2Department of Rheumatology Immunology and Allergy, Children’s Hospital, Zhejiang University School of Medicine , , ,
- 3China National Clinical Research Center of Respiratory Diseases, Respiratory Department, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health , ,
- 4Division of Pediatric Pulmonology, Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China , ,
- 5Department of Pediatrics, Jinhua Hospital of TCM Affiliated to Zhejiang University of Traditional Chinese Medicine , ,
- 6Jinhua Municipal Central Hospital, Shaoxing University , ,
- 7College of Life Sciences, Zhejiang Normal University , ,
Abstract
β-Lactams and macrolides are two cornerstone classes of antimicrobials in clinical practice. Traditionally, this combination was considered potentially antagonistic. However, accumulating evidence from basic and clinical research has begun to challenge this view and indicates that the two classes may exert complementary and synergistic effects in specific clinical contexts. This review first describes the mechanisms of action and resistance of both antibiotic classes, and then presents clinical evidence supporting the use of combination therapy. The greatest clinical benefit of combination therapy is observed in adults with severe community-acquired pneumonia (CAP). By contrast, results from non-severe CAP or pediatric populations have been inconsistent. We then systematically review potential synergistic mechanisms, including complementary antibacterial targets, macrolide penetration facilitated by β-lactam-induced cell-wall injury, suppression of bacterial repair and stress responses, biofilm disruption, immunomodulation, and quorum-sensing interference. We also classify the strength of evidence for each proposed mechanism. Finally, we compare the pharmacokinetic/pharmacodynamic (PK/PD) profiles of azithromycin, clarithromycin, and erythromycin and assess their potential impact on combination efficacy. We also discuss safety concerns, including adverse effects, drug interactions, and selection for resistance, along with strategies to address these issues. It should be emphasized that most mechanistic evidence derives from in vitro or animal studies, and only a minority comes from clinical research. The combination should be used with strict attention to indications, and its benefits should not be extrapolated indiscriminately to other conditions. We conclude that β-lactam-macrolide combination therapy demonstrates promising synergy in severe CAP and other specific infections. The multi-level mechanistic framework lends biological plausibility to the observed synergy, but biological synergy does not guarantee clinical benefit in all patients. Only when used in the right patients, at the right time, and with the right drug combination can this therapeutic strategy produce clinical benefit.
Related
- Host-response biomarker panels for distinguishing selected acute respiratory viral-bacterial co-infections from mono-infections
- Albumin for people with liver cirrhosis and bacterial infections
- Multiple Neurological Complications and Multidrug-Resistant Bacterial Infections During Prolonged Intensive Care for Undocumented Meningoencephalitis in Côte d'Ivoire: A Case Report
- Surveillance of bacterial and fungal infections in hospitalised COVID-19 patients: an ISARIC/WHO CCP-UK and UKHSA linkage study
- Artificial intelligence-driven identification and mechanistic exploration of synergistic anti-aging compounds from Dengzhan Shengmai formulation
BibTeX
@article{lu2026mechanistic,
title = {{Mechanistic insights into the synergistic interactions between macrolides and beta-lactams in bacterial infections}},
author = {Qiaochun Lu and Xubo Qian and Yandie Li and Yao Liu and Zijin Chen and Le He and Yilin Yu and Zhigang Jin and Yuting Shi},
journal = {Frontiers in cellular and infection microbiology},
year = {2026},
month = oct,
doi = {10.3389/fcimb.2026.1894766},
url = {https://europepmc.org/article/PMC/PMC13717396},
note = {CC BY},
}
RIS
TY - JOUR
TI - Mechanistic insights into the synergistic interactions between macrolides and beta-lactams in bacterial infections
AU - Qiaochun Lu
AU - Xubo Qian
AU - Yandie Li
AU - Yao Liu
AU - Zijin Chen
AU - Le He
AU - Yilin Yu
AU - Zhigang Jin
AU - Yuting Shi
PY - 2026
DA - 2026/10/15
JO - Frontiers in cellular and infection microbiology
DO - 10.3389/fcimb.2026.1894766
UR - https://europepmc.org/article/PMC/PMC13717396
AB - β-Lactams and macrolides are two cornerstone classes of antimicrobials in clinical practice. Traditionally, this combination was considered potentially antagonistic. However, accumulating evidence from basic and clinical research has begun to challenge this view and indicates that the two classes may exert complementary and synergistic effects in specific clinical contexts. This review first describes the mechanisms of action and resistance of both antibiotic classes, and then presents clinical evidence supporting the use of combination therapy. The greatest clinical benefit of combination therapy is observed in adults with severe community-acquired pneumonia (CAP). By contrast, results from non-severe CAP or pediatric populations have been inconsistent. We then systematically review potential synergistic mechanisms, including complementary antibacterial targets, macrolide penetration facilitated by β-lactam-induced cell-wall injury, suppression of bacterial repair and stress responses, biofilm disruption, immunomodulation, and quorum-sensing interference. We also classify the strength of evidence for each proposed mechanism. Finally, we compare the pharmacokinetic/pharmacodynamic (PK/PD) profiles of azithromycin, clarithromycin, and erythromycin and assess their potential impact on combination efficacy. We also discuss safety concerns, including adverse effects, drug interactions, and selection for resistance, along with strategies to address these issues. It should be emphasized that most mechanistic evidence derives from in vitro or animal studies, and only a minority comes from clinical research. The combination should be used with strict attention to indications, and its benefits should not be extrapolated indiscriminately to other conditions. We conclude that β-lactam-macrolide combination therapy demonstrates promising synergy in severe CAP and other specific infections. The multi-level mechanistic framework lends biological plausibility to the observed synergy, but biological synergy does not guarantee clinical benefit in all patients. Only when used in the right patients, at the right time, and with the right drug combination can this therapeutic strategy produce clinical benefit.
SN - 2235-2988
ER -